Christopher P Cannon 1, Richard Pratley 1, Samuel Dagogo-Jack 1, James Mancuso 1, Susan Huyck 1, Urszula Masiukiewicz 1, Bernard Charbonnel 1, Robert Frederich 1, Silvina Gallo 1, Francesco Cosentino 1, Weichung J Shih 1, Ira Gantz 1, Steven G Terra 1, David Z I Cherney 1, Darren K McGuire 1, VERTIS CV Investigators
Main idea: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.
Abstract: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.
Methods: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease. The primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome. The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.
Results: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients. Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients.
Source NIH
Leave a Reply
You must be logged in to post a comment.